| Adipose-derived Stromal Vascular Fraction Cells to Treat Parkinson (NCT05699161) | Samuel Vilchez, PhD | 2021-10-14 |
| Feasibility of Motor-cognitive Home Training for Parkinson's Disease Using eHealth Technology (NCT05027620) | Stiftelsen Stockholms Sjukhem | 2021-10-05 |
| Effect of Meditation and Controls and Subjects With Parkinson's Disease on Brain Activity Measured by fMRI With FDOPA (NCT05103618) | Andrew Newberg | 2021-07-08 |
| Multicenter Study of Blood Biomarkers of Mitochondrial and Peroxisomal Metabolism to Differentiate Idiopathic Parkinson's Disease From Related Conditions (NCT05110547) | Centre Hospitalier Universitaire Dijon | 2021-04-27 |
| FDOPA PET and Nutritional Support in Parkinson's Disease (NCT04459052) | Thomas Jefferson University | 2020-04-30 |
| Effect of Safinamide on Parkinson's Disease Related Chronic Pain (NCT03841604) | Zambon SpA | 2019-04-09 |
| A Study to Evaluate in Patients With Parkinsonian Type Disorders (NCT03683225) | Chase Therapeutics Corporation | 2019-04-01 |
| Molecular Pathology and Neuronal Networks in LRRK2 Parkinson's Disease (NCT03782753) | King's College London | 2019-02-15 |
| The Natural History of Parkinson's Disease-associated Spinal Disorders (NCT04101513) | Ohio State University | 2019-02-14 |
| Lundbeck TOMs Orthostatic Hypotension (NCT04510922) | Alberto Espay, MD, MSc | 2019-02-11 |
| Intravenous Plasma Treatment for Parkinson's Disease (NCT04202757) | The Neurology Center | 2018-09-24 |
| Voice Treatment for Parkinson's Disease (NCT03700684) | University of Massachusetts, Amherst | 2018-09-19 |
| Clinical Outcome Assessment of Parkinson's Disease Patients Treated With XADAGO (Safinamide) (NCT03944785) | Supernus Pharmaceuticals, Inc. | 2017-11-30 |
| Safety and Tolerability of Tozadenant as Adjunctive Therapy in Levodopa-Treated Patients With Parkinson's Disease. (NCT03051607) | Biotie Therapies Inc. | 2017-04-10 |
| Measuring Parkinson's Disease With Tear Fluid (NCT03037463) | University of Southern California | 2017-01-01 |
| tDCS for Treatment of Depression in Parkinson's Disease (NCT02960464) | Hospital Santa Marcelina | 2016-10-01 |
| Sleep, Awake & Move - Part I (NCT02723396) | Neurocenter of Southern Switzerland | 2016-03-16 |
| PA Behavior and HRQoL in Parkinson's Disease Patients Patients: Role of Social Cognitive Variables (NCT05575479) | Ohio State University | 2015-08-01 |
| Quantification of Dopamine Active Transporter (DAT) in Humans: Validation of a New Radiophamaceutical, the [18F] LBT-999 (NCT02393027) | University Hospital, Tours | 2015-03-01 |
| A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of PF-06649751 in Subjects With Idiopathic Parkinson's Disease (NCT02373072) | Pfizer | 2015-03-01 |
| Parkinsonian Brain Repair Using Human Stem Cells (NCT02780895) | Celavie Bioscences, LLC | 2014-05-01 |
| Physiological Effects of Nutritional Support in Patients With Parkinson's Disease (NCT02445651) | Thomas Jefferson University | 2014-03-01 |
| Evaluation of Safety and Tolerability of Fetal Mesencephalic Dopamine Neuronal Precursor Cells for Parkinson's Disease (NCT01860794) | Bundang CHA Hospital | 2013-05-01 |
| GDNF in ideopathicParkinsons Disease (NCT03652363) | North Bristol NHS Trust | 2012-10-25 |
| Study to Determine Mutations in the Gaucher Gene in Patients With Idiopathic Parkinson's Disease for Phenotype-genotype Correlation (NCT01272687) | CENTOGENE GmbH Rostock | 2011-01-01 |
| Placebo Controlled Study of Preladenant in Participants With Moderate to Severe Parkinson's Disease (P07037) (NCT01227265) | Merck Sharp & Dohme LLC | 2010-11-19 |
| An Active-Controlled Extension Study to NCT01155466 [P04938] and NCT01227265 [P07037] (P06153) (NCT01215227) | Merck Sharp & Dohme LLC | 2010-11-18 |
| Study on the Tolerability of Duloxetine in Depressed Patients With Parkinson's Disease (NCT00437125) | Eli Lilly and Company | 2007-03-01 |
| Transdermal Rotigotine User Surveillance Study (NCT00599339) | UCB Pharma | 2006-06-01 |
| Levetiracetam Treatment in Adult Subjects With Parkinson's Disease Experiencing Troublesome Dyskinesias (NCT00160576) | UCB Pharma | 2003-07-01 |